Last reviewed · How we verify
Vasopressin V2 Receptor Antagonist
Vasopressin V2 Receptor Antagonist is a Small molecule drug developed by Sanofi. It is currently in Phase 2 development.
At a glance
| Generic name | Vasopressin V2 Receptor Antagonist |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (PHASE2)
- Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 (PHASE3)
- Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (PHASE3)
- Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (PHASE3)
- The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (PHASE2)
- A Trial to Study BAY1753011 in Patients With Congestive Heart Failure (PHASE2)
- Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt (NA)
- Tolvaptan for Advanced or Refractory Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressin V2 Receptor Antagonist CI brief — competitive landscape report
- Vasopressin V2 Receptor Antagonist updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Vasopressin V2 Receptor Antagonist
What is Vasopressin V2 Receptor Antagonist?
Vasopressin V2 Receptor Antagonist is a Small molecule drug developed by Sanofi.
Who makes Vasopressin V2 Receptor Antagonist?
Vasopressin V2 Receptor Antagonist is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What development phase is Vasopressin V2 Receptor Antagonist in?
Vasopressin V2 Receptor Antagonist is in Phase 2.
Related
- Manufacturer: Sanofi — full pipeline
- Compare: Vasopressin V2 Receptor Antagonist vs similar drugs
- Pricing: Vasopressin V2 Receptor Antagonist cost, discount & access